[go: up one dir, main page]

CA2284910A1 - Pharmaceutical combined preparations containing erythropoietin and iron preparations - Google Patents

Pharmaceutical combined preparations containing erythropoietin and iron preparations Download PDF

Info

Publication number
CA2284910A1
CA2284910A1 CA002284910A CA2284910A CA2284910A1 CA 2284910 A1 CA2284910 A1 CA 2284910A1 CA 002284910 A CA002284910 A CA 002284910A CA 2284910 A CA2284910 A CA 2284910A CA 2284910 A1 CA2284910 A1 CA 2284910A1
Authority
CA
Canada
Prior art keywords
preparations
iron
containing erythropoietin
pharmaceutical
pharmaceutical combined
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002284910A
Other languages
French (fr)
Other versions
CA2284910C (en
Inventor
Paul Lehmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2284910A1 publication Critical patent/CA2284910A1/en
Application granted granted Critical
Publication of CA2284910C publication Critical patent/CA2284910C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Clamps And Clips (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to a pharmaceutical combined preparation comprising 250 -20,000 U of an EPO preparation in an individual form of administration and 5-20 mg of an Fe(III) complex. Said EPO preparation and said Fe(III) complex can be made available in a separate or homogeneous form of administration. Said pharmaceutical preparation is used for treating anemic or hemodialysis patients.
CA002284910A 1997-03-18 1997-03-18 Pharmaceutical combined preparations containing erythropoietin and iron preparations Expired - Lifetime CA2284910C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1997/001343 WO1998041226A1 (en) 1997-03-18 1997-03-18 Pharmaceutical combined preparations containing erythropoietin and iron preparations

Publications (2)

Publication Number Publication Date
CA2284910A1 true CA2284910A1 (en) 1998-09-24
CA2284910C CA2284910C (en) 2003-01-28

Family

ID=8166555

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002284910A Expired - Lifetime CA2284910C (en) 1997-03-18 1997-03-18 Pharmaceutical combined preparations containing erythropoietin and iron preparations

Country Status (19)

Country Link
US (1) US6710028B2 (en)
EP (1) EP0977582B1 (en)
JP (1) JP2000514092A (en)
AT (1) ATE222118T1 (en)
AU (1) AU726801B2 (en)
BR (1) BR9714632A (en)
CA (1) CA2284910C (en)
CZ (1) CZ296960B6 (en)
DE (1) DE59707988D1 (en)
DK (1) DK0977582T3 (en)
ES (1) ES2180958T3 (en)
HU (1) HU226204B1 (en)
IL (2) IL131959A0 (en)
NO (1) NO324661B1 (en)
NZ (1) NZ337465A (en)
PL (1) PL187479B1 (en)
PT (1) PT977582E (en)
SI (1) SI0977582T1 (en)
WO (1) WO1998041226A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US20040198663A1 (en) * 2003-04-04 2004-10-07 Baker John E. Method of treating cardiac ischemia by using erythropoietin
WO2005000340A1 (en) * 2003-06-27 2005-01-06 Pomytkin Igor A Synergistic compositions comprising erythropoietin and succinic acid (salt)
CN1901934B (en) * 2003-12-19 2013-09-11 弗·哈夫曼-拉罗切有限公司 Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
ES2962777T3 (en) 2007-11-15 2024-03-21 Amgen Inc Antioxidant-stabilized aqueous antibody formulation for parenteral administration
EP2067752A1 (en) * 2007-12-06 2009-06-10 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Construction material
US8536106B2 (en) 2010-04-14 2013-09-17 Ecolab Usa Inc. Ferric hydroxycarboxylate as a builder
EP2576587B1 (en) 2010-05-24 2018-03-21 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US4745099A (en) 1985-02-06 1988-05-17 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of malignant tumors
NO881507D0 (en) * 1987-04-10 1988-04-07 Ortho Pharma Corp PROCEDURE FOR INCREASING THE HEMATOCRIT LEVEL FOR A NORMAL MAMMAL.
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
DE19535571A1 (en) * 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Combined pharmaceutical preparations and their use for the treatment of hemodialysis patients
EP0885613A1 (en) * 1997-06-21 1998-12-23 Roche Diagnostics GmbH Use of modified hemoglobins for treatment of anemias and erythropoietin and modified hemoglobin containing combined preparations
DE19734293A1 (en) * 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Use of pharmaceutical combination preparations containing erythropoietin and iron preparations for the treatment of rheumatic diseases
US20020065214A1 (en) * 2000-11-29 2002-05-30 Adrian Iaina Method of treating congestive heart failure
JP4656814B2 (en) * 2000-12-20 2011-03-23 エフ．ホフマン−ラ ロシュ アーゲー Erythropoietin conjugate

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7304150B1 (en) 1998-10-23 2007-12-04 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US7973009B2 (en) 1998-10-23 2011-07-05 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US7977311B2 (en) 1998-10-23 2011-07-12 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
US8268588B2 (en) 1998-10-23 2012-09-18 Amgen Inc. Methods and compositions for the prevention and treatment of anemia

Also Published As

Publication number Publication date
CZ296960B6 (en) 2006-08-16
DE59707988D1 (en) 2002-09-19
HUP0001409A2 (en) 2001-03-28
AU2157297A (en) 1998-10-12
EP0977582A1 (en) 2000-02-09
PT977582E (en) 2002-12-31
CZ9903300A3 (en) 2001-03-14
US6710028B2 (en) 2004-03-23
HU226204B1 (en) 2008-06-30
ES2180958T3 (en) 2003-02-16
HUP0001409A3 (en) 2003-08-28
NO994511L (en) 1999-09-17
NZ337465A (en) 2002-04-26
US20020094948A1 (en) 2002-07-18
DK0977582T3 (en) 2002-12-16
PL335858A1 (en) 2000-05-22
CA2284910C (en) 2003-01-28
NO994511D0 (en) 1999-09-17
SI0977582T1 (en) 2002-12-31
IL131959A (en) 2006-12-31
BR9714632A (en) 2000-05-23
WO1998041226A9 (en) 1999-11-25
WO1998041226A1 (en) 1998-09-24
ATE222118T1 (en) 2002-08-15
JP2000514092A (en) 2000-10-24
IL131959A0 (en) 2001-03-19
AU726801B2 (en) 2000-11-23
PL187479B1 (en) 2004-07-30
EP0977582B1 (en) 2002-08-14
NO324661B1 (en) 2007-11-26

Similar Documents

Publication Publication Date Title
AU7128296A (en) Pharmaceutical combination preparations containing erythropoietin and iron preparations
GR3017686T3 (en) Fluorocytidine derivatives, their preparation and medical preparations containing them.
CA2284910A1 (en) Pharmaceutical combined preparations containing erythropoietin and iron preparations
CA2087146A1 (en) Flavour-masked pharmaceutical compositions
AU5068593A (en) Macrocyclic aminophosphonic acid complexes, their preparation, formulations and use
CA2294448A1 (en) Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
CA2280773A1 (en) Methods for the administration of amifostine
IL91087A0 (en) Platinum-(iv)-diamine complexes,their preparation and pharmaceutical compositions containing them
CA2057493A1 (en) A process for the preparation of a pasteurized and iron-free human transferrin
CA2127107A1 (en) Methods and compositions for reducing blood loss
AU5647096A (en) Combined preparations with vascular effect containing dihydr opyridines, acetylsalicylic acid nitroesters and vitamins
TR199902305T2 (en) Pharmaceutical combination preparations containing erythropoitein and iron preparations.
GR3002381T3 (en) Use of a carboxylic acid in pharmaceutical preparations intended for topical application
AU2076288A (en) 11beta-phenyl-4,9,15-estratrienes, their manufacture, and pharmaceutical preparations containing them
CA2171460A1 (en) Preparation for substitution therapy, containing at least one progestogen and at least one extrogen
AU6060290A (en) Blood/solution administration sets and components therefor

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20170320